Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Overview
Explore Rhythm Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.7B
P/E Ratio
-33.33
EPS (TTM)
$-3.10
ROE
-1.66%
RYTM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Rhythm Pharmaceuticals, Inc. (RYTM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 44.77, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $150.25.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -33.33 and a market capitalization of 6.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.